All In Biotech

Drug Trial Radar · NCT05686239

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Dec 8, 2022

Primary completion

Apr 9, 2025

Study completion Apr 9, 2025

Sponsor

Lead sponsor
Recognify Life SciencesIndustry
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with the tasks. Then, subjects will be given either RL-007 or a placebo for 6 weeks and then repeat the cognitive tasks. The researchers will compare the results at the end of the treatment period to the baseline to see if there have been any changes in performance. Additionally, several safety measures will be collected throughout the study (blood pressure, physical exam, ECGs, etc) to evaluate if there are any side effects from taking RL-007.

Conditions

  • Cognitive Impairment Associated With Schizophrenia (CIAS)
  • Cognitive Impairment
  • Schizophrenia

Interventions

  • RL-007 (Inidascamine)Drug

    investigational study drug

  • PlaceboDrug

    placebo capsules matching the appearance and size of the active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MATRICS Consensus Cognitive Battery (MCCB) neurocognitive compositeTime frame: 6 weeks

Locations

36 sites in 4 countries. Site status is shown where the registry gives one.

  • Recognify Research Site

    Culver City, California

  • Collaborative Neuroscience Research

    Garden Grove, California

  • Recognify Research Site

    Lafayette, California

  • Recognify Research Site

    Oceanside, California

  • Recognify Research Site

    Orange, California

  • Recognify Research Site

    Torrance, California

  • Recognify Research Site

    Hialeah, Florida

  • Recognify Research Site

    Miami, Florida

  • Recognify Research Site

    Miami Lakes, Florida

  • Recognify Research Site

    Atlanta, Georgia

  • Recognify Research Site

    Augusta, Georgia

  • Recognify Research Site

    Gaithersburg, Maryland

  • Recognify Research Site

    Berlin, New Jersey

  • Recognify Research Site

    Brooklyn, New York

  • Recognify Research Site

    Chapel Hill, North Carolina

  • Recognify Research Site

    Cincinnati, Ohio

  • Recognify Research Site

    Cleveland, Ohio

  • Recognify Research Site

    Dallas, Texas

  • Recognify Research Site

    Houston, Texas

  • Recognify Research Site

    Everett, Washington

  • Recognify Research Site

    Burgas, Bulgaria

  • Recognify Research Site

    Kardzhali, Bulgaria

  • Recognify Research Site

    Pleven, Bulgaria

  • Recognify Research Site

    Plovdiv, Bulgaria

  • Recognify Research Site

    Sofia, Bulgaria

  • Recognify Research Site (a)

    Varna, Bulgaria

  • Recognify Research Site (b)

    Varna, Bulgaria

  • Recognify Research Site

    Pilsen, Czechia

  • Recognify Research Site (a)

    Prague, Czechia

  • Recognify Research Site (b)

    Prague, Czechia

  • Recognify Research Site

    Gdansk, Poland

  • Recognify Research Site

    Gorlice, Poland

  • Recognify Research Site

    Kielce, Poland

  • Recognify Research Site

    Lodz, Poland

  • Recognify Research Site

    Lublin, Poland

  • Recognify Research Site

    Poznan, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.